Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda
pembrolizumab · Merck Sharp & Dohme
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors, who could not undergo or chose not to undergo cystectomy.
LAMPGEN ANALYSIS
Why it matters
Added a systemic immunotherapy option for patients with persistent high-risk disease considering bladder preservation.
What research teams should watch
Document prior BCG courses and surgical eligibility; standardize cystoscopy and cytology schedules.
PRIMARY RECORDS